HC Wainwright Issues Positive Estimate for RARE Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at HC Wainwright raised their Q3 2025 earnings estimates for Ultragenyx Pharmaceutical in a report released on Wednesday, August 6th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($1.15) per share for the quarter, up from their previous forecast of ($1.25). HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($4.85) EPS, Q1 2026 earnings at ($1.74) EPS, Q2 2026 earnings at ($1.51) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($0.99) EPS and FY2026 earnings at ($5.57) EPS.

Other equities research analysts have also issued research reports about the stock. Morgan Stanley dropped their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, July 14th. Guggenheim reiterated a “buy” rating and issued a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research note on Monday, July 14th. Canaccord Genuity Group dropped their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research note on Friday. Finally, William Blair began coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They issued an “outperform” rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $27.54 on Friday. Ultragenyx Pharmaceutical has a one year low of $25.81 and a one year high of $60.37. The company’s 50-day simple moving average is $33.32 and its 200 day simple moving average is $36.78. The firm has a market capitalization of $2.65 billion, a P/E ratio of -4.98 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. During the same quarter in the previous year, the firm posted ($1.52) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 13.2% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 1,061.9% during the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 669 shares during the last quarter. GAMMA Investing LLC increased its holdings in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 323 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $35,000. ANTIPODES PARTNERS Ltd purchased a new stake in Ultragenyx Pharmaceutical during the first quarter valued at approximately $57,000. Finally, Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical during the first quarter valued at approximately $59,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business’s stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares of the company’s stock, valued at $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.